CA2113644A1 - Inhibiteurs de protease retrovirale - Google Patents

Inhibiteurs de protease retrovirale

Info

Publication number
CA2113644A1
CA2113644A1 CA002113644A CA2113644A CA2113644A1 CA 2113644 A1 CA2113644 A1 CA 2113644A1 CA 002113644 A CA002113644 A CA 002113644A CA 2113644 A CA2113644 A CA 2113644A CA 2113644 A1 CA2113644 A1 CA 2113644A1
Authority
CA
Canada
Prior art keywords
amino
methyl
phenyl
hydroxy
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002113644A
Other languages
English (en)
Inventor
Thomas Joseph Carr
Peter Lawrence Demarsh
Goeffrey Bainbridge Dreyer
Ashley Edward Fenwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2113644A1 publication Critical patent/CA2113644A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/95—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by nitrogen atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA002113644A 1991-07-17 1992-07-17 Inhibiteurs de protease retrovirale Abandoned CA2113644A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73156391A 1991-07-17 1991-07-17
US07/731,563 1991-07-17
US07/870,975 1992-04-19
US87097592A 1992-04-20 1992-04-20

Publications (1)

Publication Number Publication Date
CA2113644A1 true CA2113644A1 (fr) 1993-02-04

Family

ID=27112266

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002113644A Abandoned CA2113644A1 (fr) 1991-07-17 1992-07-17 Inhibiteurs de protease retrovirale

Country Status (10)

Country Link
EP (1) EP0602069A4 (fr)
JP (1) JPH07500577A (fr)
AP (1) AP9200410A0 (fr)
AU (1) AU2412992A (fr)
CA (1) CA2113644A1 (fr)
IE (1) IE922316A1 (fr)
IL (1) IL102534A0 (fr)
MX (1) MX9204233A (fr)
PT (1) PT100704A (fr)
WO (1) WO1993002057A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
RU2126794C1 (ru) * 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
GB9207380D0 (en) * 1992-04-03 1992-05-13 Ici Plc Compounds
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
ES2068739B1 (es) * 1993-01-21 1995-11-01 Smithkline Beecham Corp Inhibidores retrovirables de proteasas.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
CA2179935C (fr) * 1995-06-30 2010-09-07 Ryohei Kato Compose dipeptidique ou sel de ce dernier acceptable en pharmacie; utilisation en medecine
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5965532A (en) 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
CA2249747A1 (fr) 1996-12-27 1998-07-09 Tsutomu Mimoto Nouveaux composes de tripeptides et medicaments anti-sida
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
ES2285785T3 (es) 1997-09-29 2007-11-16 Point Therapeutics, Inc. Estimulacion de celulas hematopoyeticas in vitro.
MY132924A (en) 1998-05-04 2007-10-31 Point Therapeutics Inc Hematopoietic stimulation
WO1999062914A1 (fr) 1998-06-05 1999-12-09 Point Therapeutics, Inc. Composes cycliques de boroproline
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
MX2021001581A (es) 2018-08-16 2021-04-19 Innate Tumor Immunity Inc Compuestos de 4-amino-1h-imidazo[4,5-c]quinolina sustituidos y metodos mejorados para su preparacion.
EP4366831A1 (fr) 2021-07-09 2024-05-15 Aligos Therapeutics, Inc. Composés anti-viraux
CN114605320B (zh) * 2022-04-06 2023-12-29 南京艾康生物科技有限公司 一种5-硝基-6-甲基烟酸乙酯的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431653A (en) * 1982-03-18 1984-02-14 Hoffmann-La Roche Inc. Penicillanic acid derivatives
IE20010533A1 (en) * 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
IL102534A0 (en) 1993-01-14
PT100704A (pt) 1993-10-29
AU2412992A (en) 1993-02-23
AP9200410A0 (en) 1992-07-31
MX9204233A (es) 1994-06-30
EP0602069A4 (fr) 1995-05-03
IE922316A1 (en) 1993-01-27
JPH07500577A (ja) 1995-01-19
WO1993002057A1 (fr) 1993-02-04
EP0602069A1 (fr) 1994-06-22

Similar Documents

Publication Publication Date Title
CA2113644A1 (fr) Inhibiteurs de protease retrovirale
DE69637380T2 (de) Bis-sulfonamid-hydroxyethylamino-derivate als inhibitoren retroviraler proteasen
JP3207901B2 (ja) レトロウイルス阻害性化合物
US5733882A (en) Retroviral protease inhibitors
EP3313832B1 (fr) Dérivés de 3-tétrazolyl-benzène-1,2-disulfonamide en tant qu'inhibiteurs de métallo-bêta-lactamase
DE69635183T2 (de) Verbindungen der Struktur Bis-Aminosäurehydroxyethylaminosulfonamid als Inhibitoren der retroviralen Protease
JP3120075B2 (ja) 化合物
EP1697348B1 (fr) Composes inhibiteurs de la protease du vih
CA2022692A1 (fr) Inhibiteurs de la renine
SK49194A3 (en) Urethanes and ureas which are inducing production of cytokine
CA2153069A1 (fr) Sulfone cyclique renfermant en partie des inhibiteurs de protease hydroxyethylamine retrovirale
JP2009545597A (ja) スフィンゴシン−１−ホスフェート受容体（ｓｌｐ）のアゴニスト
AU2005286844A1 (en) Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
CZ412898A3 (cs) Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy
CA2075547A1 (fr) Pseudopeptides contenant du trifluoromethyle
TW200524578A (en) Protease inhibitors
EP1697344B1 (fr) Composes inhibiteurs de protease du vih
US6759406B1 (en) Quaternary ammonium compounds
EP0437729A2 (fr) Nouveaux peptides, leur procédé de préparation et leur application comme médicament, notamment leur application comme médicament antiviral
CA2110381A1 (fr) Derives hydroxyazido et composes apparentes, inhibiteurs de la renine
EP1482930B1 (fr) Inhibiteurs de peptide deformylase
EP1660493A1 (fr) Derives cetones heterocycliques peptidyliques et procedes de preparation
EP3638686B1 (fr) Peptidyl-cétoamides utilisés en tant qu'inhibiteurs de protéases rohomboïdes
CZ74795A3 (en) N-(hydroxyethyl) butanediamide derivatives, process of their preparation, their use for the preparation of pharmaceuticals and pharmaceutical preparations in which said derivatives are comprised
WO1996005180A1 (fr) 1,2,4,-triazacycloheptanes inhibant la protease de retrovirus

Legal Events

Date Code Title Description
FZDE Discontinued